ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR
Resource
J. Hepatol., 56, S553-S554
Journal
J. Hepatol.
Journal Issue
56
Pages
-
Date Issued
2012
Date
2012
Author(s)
Alberti, A.
Chuang, W. -L.
Flisiak, R.
Mazzella, G.
Horban, A.
Goeser, T.
Calistru, P.
Buti, M.
Davis, G.
Gong, Y.
Avila, C.
Kao, J. -H.